BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thejeel B, Garg AX, Clark WF, Liu AR, Iansavichus AV, Hildebrand AM. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. Am J Hematol 2016;91:623-30. [PMID: 26910131 DOI: 10.1002/ajh.24339] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Sridharan M, Hook CC, Leung N, Winters JL, Go RS; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Postsurgical thrombotic microangiopathy: Case series and review of the literature. Eur J Haematol 2019;103:307-18. [PMID: 31251415 DOI: 10.1111/ejh.13284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Chabot-richards DS, Foucar K. Does morphology matter in 2017? An approach to morphologic clues in non-neoplastic blood and bone marrow disorders. Int J Lab Hem 2017;39:23-30. [DOI: 10.1111/ijlh.12667] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Sargentini-Maier ML, De Decker P, Tersteeg C, Canvin J, Callewaert F, De Winter H. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura. Expert Rev Clin Pharmacol 2019;12:537-45. [PMID: 30977686 DOI: 10.1080/17512433.2019.1607293] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
4 Pollissard L, Leinwand BI, Fournier M, Pham HP. Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective. J Med Econ 2021;24:1178-84. [PMID: 34643472 DOI: 10.1080/13696998.2021.1992413] [Reference Citation Analysis]
5 Pollissard L, Shah A, Punekar RS, Petrilla A, Pham HP. Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura. J Med Econ 2021;24:706-16. [PMID: 33904347 DOI: 10.1080/13696998.2021.1922262] [Reference Citation Analysis]
6 Galstyan GM, Maschan AA, Klebanova EE, Kalinina II. Treatment of thrombotic thrombocytopenic purpura. Terapevticheskii arkhiv 2021;93:736-45. [DOI: 10.26442/00403660.2021.06.200894] [Reference Citation Analysis]
7 Minoia F, Tibaldi J, Muratore V, Gallizzi R, Bracaglia C, Arduini A, Comak E, Vougiouka O, Trauzeddel R, Filocamo G, Mastrangelo A, Micalizzi C, Kasapcopur O, Unsal E, Kitoh T, Tsitsami E, Kostik M, Schmid JP, Prader S, Laube G, Maritsi D, Jelusic M, Shenoi S, Vastert S, Ardissino G, Cron RQ, Ravelli A; MAS/sJIA Working Group of the Pediatric Rheumatology European Society (PReS). Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. J Pediatr 2021;235:196-202. [PMID: 33836183 DOI: 10.1016/j.jpeds.2021.04.004] [Reference Citation Analysis]
8 Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv 2021;5:2137-41. [PMID: 33881463 DOI: 10.1182/bloodadvances.2020001834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Podd BS, Simon DW, Lopez S, Nowalk A, Aneja R, Carcillo JA. Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure. Pediatr Clin North Am 2017;64:1071-88. [PMID: 28941536 DOI: 10.1016/j.pcl.2017.06.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]